Fritextsökning
Artiklar per år
-
Orexo i exklusivt avtal
Drug deliverybolaget Orexo har tecknat ett exklusivt utvecklingsavtal med ett stort läkemedelsföretag. Tillsammans ska de utveckla projektet OX17 mot halsbränna.
-
Livsviktiga grödor ska bevaras
Regeringen har utsett SLU-forskaren som ska bli Sveriges koordinator i ett EU-program som ska rädda växter till framtiden.
-
Helge Sander: "Fler kvinnor behövs"
- Det är något fel när det ena könet i stort sett väljer bort en karriär som forskare, säger Danmarks forskningsminister. Idag håller han rundabordssamtal för att diskutera varför kvinnliga forskare missgynnas. Han välkomnar alla lösningar, utom en.
-
Många miljoner till Symphogen
Ägarna skjuter till ett mångmiljonbelopp som ska användas till fortsatt klinisk utveckling av bolagets antikroppar mot bland annat cancer.
-
Symphogen buys tumor blocking technology
The seller is a pioneer in developing ligand traps to treat cancer and other diseases. "An excellent fit with our scientific and strategic focus," said Kirsten Drejer, CEO of Symphogen. Ph.D.
-
Faster sales but less profits for Probi
The probiotic company increases its turnover, and the net results are twice as large as last year.
-
Pfizer lays a chunky bid on Wyeth
The merger of two pharma giants is the largest industry deal so far this year. Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at approximately $68 billion. The Boards of Directors of both companies have said yes to the deal that may lead to lay-offs of some 8,000 persons.
-
Success fee to Bioinvent and partner
The cancer collaboration started last year. After successful technology transfer the two partner companies now receives 5 million euro from pharma giant Roche.
-
Orexo opens doors eastwards
The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.
-
Less scars with new product
A new Swedish product for post surgical scar formation enters clinical development.
-
Lytix calls in cash
Norwegian company Lytix Biopharma closes a USD 1.4 million funding round to finance new antimicrobial and oncology lead compounds.
-
EU says yes to Roche drug
EU approves a first in class therapy for treatment of patients with moderate to severe form of rheumatoid arthritis.
-
Swedish nanotech crosses the Atlantic
Genovis signs distribution agreement Finnzymes in US.
-
Medtech companies find new beam technique
The medtech companies Raysearch and Nucletron expand collaboration with two new solutions for radiation treatment planning.
-
New NO product reduces diabetic pain
The Swedish medtech company Nolabs has announced that it has achieved an important milestone in the development of a new line of products.
-
Dako appoints new CEO
The Danish cancer therapeutic company Dako has appointed a new CEO after Patrik Dahlén.
-
Think outside the... brain
Riitta Hari from the Brain Research Unit at the Helsinki University of Technology has recently stated that the mind is more than just the brain.
-
Woman deficit in Swedish research
The IP firm Awapatent will soon launch its Innovation Barometer 2009. This year Awapatent reveals that the statistics is even worse, compared to last year.
-
Eli Lilly writes biotech fine history
The American biotech company Eli Lilly will pay US 1.415 billion to resolve allegations of off-label promotion of a dementia drug.
-
Polymer guru new dean at DTU
The Technical University of Denmark, DTU, has appointed a well-known profile from the Polymer Center as a new dean.
-
New map of eye proteins
A new mapping of proteins in the eye opens the door for new treatments of eye diseases in the future.
-
Travelling scholarship to DTU professor
The Vera og Carl Johan Michaelsens Rejselegat has the founder of the Medicine and Technology program at DTU with a scholarship.
-
View pathology images in your iPhone
The Institute for Medical Informatics in Oslo announces a brand new iPhone application for virtual microscopy.
-
Norwegian cancer therapy leaves phase II
New clinical results from Algeta highlights the potential of Alpharadin to treat bone metastases in major cancer indications.
BREAKING